Skip to search formSkip to main contentSkip to account menu

Protein Stabilized Liposomal Docetaxel Nanoparticles

Known as: ATI-1123 
A formulation containing protein-stabilized liposome nanoparticles encapsulating the poorly water-soluble, second-generation taxane analog docetaxel… 
National Institutes of Health

Related topics

Related topics

1 relation
Microtubule Process

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Phase I study of ATI-1123, a novel human serum albumin-stabilized docetaxel liposomal formulation, in patients with advanced solid malignancies.
2609 Background: Liposomal (LIPO) docetaxel (DOCE) formulations may reduce hypersensitivity reactions, eliminate premedication… 
2007
2007
Pharmacokinetic study of ATI-1123 (docetaxel) Azaya Therapeutics protein stabilized liposome technology (PSLTM)
1509 Background: Docetaxel is a semi-synthetic taxane analog commonly used in the treatment of non-small cell lung, prostate, and… 
2007
2007
Comparative human tumor xenograft studies of docetaxel encapsulated with azaya therapeutics protein stabilized liposome (PSLTM) nanotechnology (ATI-1123) and standard docetaxel
2255 Docetaxel is a poorly water-soluble semi-synthetic taxane analog commonly used in the treatment of non-small cell lung… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)